Cost-effectiveness analysis of domestic 13-valent pneumococcal conjugate vaccine for children under 5 years of age in mainland China
Authors:
- 12 February 2021
- journal article
- research article
- Published by Taylor & Francis in Human Vaccines & Immunotherapeutics
- Vol. 17 (7) , 2241-2248
Abstract
Background: The first Chinese domestic 13-valent pneumococcal conjugate vaccine (WoAnxin®, PCV-13) is available for children aged 2 months to 5 years and is more economical than import vaccine with equal safety and immunogenicity. However, the cost-effectiveness of this new PCV-13 for children <5 years in mainland China is not clear. Methods: In the present study, we developed a Markov model under societal perspective to evaluate the incremental cost-effectiveness ratios (ICERs) of five birth cohorts of 100,000 Chinese infants across four alternative vaccination programs:1) no vaccination; 2) vaccinate 4 doses of new PCV-13 for children aged 2 to 6 months; 3) vaccinate 3 doses of new PCV-13 for children aged 7 to 11 months; 4) vaccinate 2 doses of new PCV-13 for children aged 12 to 23 months; 5) vaccinate 1 dose of new PCV-13 for children aged 2 to 5 years. We conducted one-way and probability sensitivity analysis to determine the uncertainty of the model findings. Results: We found that with awillingness-to-pay (WTP) threshold of three-times Chinese per-capita gross domestic product (GDP) all vaccination programs were cost-effective compared to no vaccination and children aged 2 to 5 years received 1 dose of new PCV-13 would incur the lowest additional cost of US$2417 per quality-adjusted-life-years (QALYs) compare with other vaccination programs ($15394/QALYs for 4 doses program, $9292/QALYs for 3 doses program, $4445/QALYs for 2 doses program). Conclusions: According to our results, China should give priority to incorporating new PCV-13 into its national immunization program.Keywords
Funding Information
- National Natural Science Foundation of China (71863023, and 82060614)
- Natural Science Foundation of Gansu (18JR3RA043)
This publication has 30 references indexed in Scilit:
- Childhood vaccines and antibiotic use in low- and middle-income countriesNature, 2020
- Pneumococcal Disease: A Systematic Review of Health Utilities, Resource Use, Costs, and Economic Evaluations of InterventionsValue in Health, 2019
- Estimating the cost-effectiveness of an infant 13-valent pneumococcal conjugate vaccine national immunization program in ChinaPLOS ONE, 2018
- Burden of Streptococcus pneumoniae and Haemophilus influenzae type b disease in children in the era of conjugate vaccines: global, regional, and national estimates for 2000–15The Lancet Global Health, 2018
- Cost-effectiveness analysis of 13-valent pneumococcal conjugate vaccine versus 23-valent pneumococcal polysaccharide vaccine in an adult population in South KoreaHuman Vaccines & Immunotherapeutics, 2018
- Cost-effectiveness analysis of routine 13-valent pneumococcal conjugate vaccinations in Chinese infantsHuman Vaccines & Immunotherapeutics, 2018
- Cost-effectiveness of the Haemophilus influenzae type b vaccine for infants in mainland ChinaHuman Vaccines & Immunotherapeutics, 2017
- Cost-effectiveness analysis of pneumococcal vaccination for infants in ChinaVaccine, 2016
- Safety and immunogenicity of a new 13-valent pneumococcal conjugate vaccine versus a licensed 7-valent pneumococcal conjugate vaccine: a study protocol of a randomised non-inferiority trial in ChinaBMJ Open, 2016
- Advances in pneumococcal antibiotic resistanceExpert Review of Respiratory Medicine, 2013